Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral anticoagulants: implications for patients with atrial fibrillation

Expert Opinion on Drug Metabolism & Toxicology
Qinmei XiongGregory Y H Lip

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs) have been developed to prevent ischemic stroke and systemic thromboembolism in patients with nonvalvular atrial fibrillation. Owing to their predictable pharmacological profiles, they can be given in fixed doses without the need for routine coagulation monitoring. However, their distinctive pharmacological properties also raise issues about potential drug interactions. A literature search was conducted to extract published studies on the pharmacodynamics and drug interactions involving NOACs. Available data from US FDA and European Medicine Agency were also included. As these agents are substrates of permeability glycoprotein (P-gp) efflux transporter and/or CYP3A4 enzymes, articles focusing on the co-administration of NOACs and drugs affecting these pathways are discussed. Concomitant use of NOACs with antiplatelet agents may potentially increase bleeding risk. Measurement of anticoagulant effects is desired to evaluate the risk of thromboembolism or bleeding for patients with NOACs. Prescribers should be vigilant against combination prescription of NOACs with strong inhibitors (such as ketoconazole) or inducers of P-gp and/or CYP3A4 (such as rifampicin). Potential benefit o...Continue Reading

References

Nov 17, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechWilly Roth
Jan 31, 2009·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Joachim StangierWilly Roth
Sep 1, 2009·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN RE-LY Steering Committee and Investigators
Nov 27, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lifei WangScott J Grossman
Apr 26, 2011·The Journal of Pharmacology and Experimental Therapeutics·Mark Jean GnothSteffen Sandmann
Jul 26, 2011·The New England Journal of Medicine·John H AlexanderUNKNOWN APPRAISE-2 Investigators
Aug 9, 2011·Journal of Cardiovascular Pharmacology·Kenneth Todd MoorePaul Bryan Burton
Aug 13, 2011·The New England Journal of Medicine·Manesh R PatelUNKNOWN ROCKET AF Investigators
Aug 30, 2011·The New England Journal of Medicine·Christopher B GrangerUNKNOWN ARISTOTLE Committees and Investigators
Feb 22, 2012·British Journal of Clinical Pharmacology·Sebastian HärtterPaul A Reilly
Jul 12, 2012·European Journal of Clinical Pharmacology·Sebastian HärtterJeffrey Friedman
Sep 6, 2012·British Journal of Clinical Pharmacology·Sebastian HärtterPaul Reilly
Sep 27, 2012·American Journal of Clinical Pathology·Joyce CurversVolkher Scharnhorst
Dec 6, 2012·British Journal of Clinical Pharmacology·Xavier DelavennePatrick Mismetti
Jan 12, 2013·British Journal of Clinical Pharmacology·Wolfgang MueckMichael Becka
Feb 6, 2013·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donglu ZhangW Griffith Humphreys
Mar 1, 2013·Thrombosis and Haemostasis·Raffaele De CaterinaUNKNOWN European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease
Jun 12, 2013·Circulation Journal : Official Journal of the Japanese Circulation Society·Hisao OgawaUNKNOWN APPRAISE-J investigators
Jun 21, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeanne MendellMinggao Shi
Jul 13, 2013·Thrombosis and Haemostasis·A BernardD Angoulvant
Jul 31, 2013·Journal of the American Pharmacists Association : JAPhA·Pranav K GandhiMichael B Bottorff
Nov 21, 2013·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN ENGAGE AF-TIMI 48 Investigators

❮ Previous
Next ❯

Citations

May 8, 2021·Biochemical and Biophysical Research Communications·Yue-Yue WangJi-Yu Gong
Sep 21, 2021·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·İbrahim Ersoy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.